Dengue Testing Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 436.19 Million |
| Market Size (2029) | USD 540.20 Million |
| CAGR (2024 - 2029) | 4.37 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Dengue Testing Market Analysis
The Dengue Testing Market size is estimated at USD 436.19 million in 2024, and is expected to reach USD 540.20 million by 2029, at a CAGR of 4.37% during the forecast period (2024-2029).
The Dengue Testing Market is witnessing significant growth due to the increasing global prevalence of dengue fever and the heightened focus on early detection and preventive measures. This market is primarily driven by two major forces: the rising number of dengue cases worldwide and the widespread awareness campaigns designed to educate the public on the risks associated with dengue.
Increasing Incidences of Dengue Cases: Dengue fever has evolved into a global health threat, with nearly half of the world's population now at risk. The rise in dengue cases is linked to various factors, including insufficient funding for effective mosquito control initiatives in many regions. Furthermore, rapid urbanization combined with poor sanitation practices has led to the proliferation of mosquito breeding sites. Climate change has also expanded the habitats of dengue-carrying mosquitoes, resulting in the spread of the disease to new regions, further exacerbating the problem.
Increasing Awareness Campaigns to Educate About the Ills of Dengue: Global governments and healthcare organizations recognize the role of public awareness in the battle against dengue. Public health campaigns are geared towards educating communities on prevention methods, such as the elimination of mosquito breeding grounds. These campaigns also focus on recognizing early symptoms and the importance of prompt medical consultation, encouraging community engagement in the fight against dengue.
Singapore: The National Environment Agency's National Dengue Prevention Campaign educates the public about reducing mosquito habitats.
Philippines: The Department of Health's 2022 campaign in Soccsksargen was launched to counteract rising dengue cases.
India: Delhi's '10 Hafte 10 Baje 10 Minute' campaign highlights preventive measures against dengue.
These campaigns are essential in promoting early testing and driving demand for dengue diagnostic tests, contributing significantly to the market's growth.
The convergence of these factors—rising dengue cases and effective public awareness campaigns—is creating a conducive environment for the expansion of the Dengue Testing Market. As public knowledge of dengue continues to rise and governments enhance their responses, the demand for precise and timely testing solutions will inevitably surge, fostering market growth in the foreseeable future.
Dengue Testing Market Trends
ELISA-based Tests: Dominating the Dengue Testing Landscape
Segment Overview: ELISA-based tests continue to dominate the dengue diagnostic landscape, capturing around 45% of the total market. These tests are favored due to their high accuracy in detecting dengue-specific antibodies, particularly IgM and IgG, which are key indicators of the stage of infection.
Growth Drivers and Future Outlook: The growing incidence of dengue cases globally, paired with increasing awareness of early diagnosis, is driving the demand for ELISA-based tests. Innovations that improve the accuracy and speed of ELISA tests are further strengthening their position. As dengue remains a pressing public health issue, ELISA-based tests are expected to maintain their leadership due to their ability to deliver timely and precise results essential for dengue management.
Competitive Strategies and Disruptions: Leading market players are focusing on developing highly sensitive ELISA kits capable of distinguishing between dengue serotypes. Automation in ELISA processes is being explored to increase efficiency and minimize human error. Despite their dominant position, ELISA-based tests face competition from rapid diagnostic tests and molecular techniques. For continued market dominance, manufacturers must innovate, potentially integrating with point-of-care solutions to meet the evolving needs of healthcare professionals.
Asia-Pacific: The Epicenter of Dengue Testing Market Growth
Regional Dynamics: The Asia-Pacific region is at the forefront of the dengue testing market’s expansion. With countries like India, Indonesia, and the Philippines facing a heavy dengue burden, the demand for diagnostic tests is rapidly increasing. The region is projected to grow at a rate of 5% per year between 2024 and 2029, outpacing other regions in dengue testing market growth.
Catalysts for Regional Growth: Factors contributing to this growth include the expansion of mosquito habitats due to climate change and urbanization, which has heightened dengue transmission risks. Additionally, increasing government initiatives aimed at dengue prevention are fueling awareness and driving the demand for dengue testing. Improvements in healthcare infrastructure, coupled with rising healthcare expenditures, are facilitating the adoption of advanced diagnostic tools across the region.
Strategic Imperatives and Future Challenges: Companies must adopt localization strategies to capitalize on the region's growth potential. Developing diagnostic tests that address specific regional dengue strains and align with local healthcare systems is crucial. Collaborating with local governments and healthcare providers is key for market penetration. However, navigating the region's complex regulatory landscape remains a challenge. Additionally, the emergence of other vector-borne diseases may divert resources, necessitating adaptable strategies for dengue test manufacturers.
Dengue Testing Industry Overview
Market Dominance: Global Players Lead Consolidated Market
The Dengue Testing Market is dominated by a few global players, primarily large conglomerates with diversified healthcare portfolios. These players, including Abbott Laboratories, PerkinElmer Inc. (EUROIMMUN AG), and DiaSorin, control a significant share of the market. Their extensive resources and global distribution networks enable them to maintain market leadership. These companies offer a broad range of diagnostic solutions, covering ELISA-based tests, RT-PCR tests, and rapid diagnostic kits, positioning themselves as comprehensive providers in the dengue testing ecosystem.
Market Leaders: Innovation and Diversification Drive Success
Leading companies in the Dengue Testing Market share key strategies that fuel their dominance. Firstly, their strong emphasis on research and development allows them to innovate continually, improving test accuracy and reducing turnaround times. For example, in August 2024, J Mitra & Company launched the Dengue NS1 Antigen self-test kit, making it one of the first home-test kits of its kind in India. Secondly, market leaders offer diversified product lines that cater to the entire dengue testing spectrum, from NS1 antigen tests to IgM and IgG antibody assays. Lastly, their established global distribution channels allow these companies to cater to high-burden regions, particularly in the Americas and Asia-Pacific.
Strategies for Future Success: Technological Advancements and Market Expansion
To increase market share and sustain leadership, key players must focus on several strategic imperatives:
Technological Advancements: Investing in biosensor-based diagnostics and molecular testing methods to develop more accurate and sensitive dengue tests.
Portable and Rapid Diagnostics: Developing point-of-care solutions, particularly for resource-limited settings, will be critical in addressing the needs of underserved populations.
Product Diversification: Expanding test portfolios to include multiplex assays for simultaneous detection of multiple arboviruses will provide a competitive edge.
Strategic Partnerships: Collaborating with local healthcare providers and government agencies in dengue-endemic regions will be vital for market penetration and expansion.
Cost-Effective Solutions: Reducing the cost of test kits to make them more accessible in developing regions will be crucial for long-term growth.
Dengue Testing Market Leaders
-
Thermo Fisher Scientific Inc.
-
InBios International, Inc.
-
NovaTec Immundiagnostica GmbH
-
F. Hoffmann-La Roche Ltd.
-
Abbott
*Disclaimer: Major Players sorted in no particular order
Dengue Testing Market News
- May 2024: WHO supported the procurement of diagnostic products and related laboratory items for the diagnosis and management of many communicable and non-communicable diseases including Dengue infections.
- October 2023: UNICEF delivered dengue testing kits to hospitals across Bangladesh, including Shaheed Ahsan Ullah Master General Hospital, through the Centre for Disease Control (CDC) under the Directorate General of Health Services.
Dengue Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase Incidences of Dengue Cases
- 4.2.2 Increasing Awareness Campaigns to Educate About the Ills of Dengue
-
4.3 Market Restraints
- 4.3.1 Unavailability of Effective Diagnostic Tools
- 4.3.2 High Price of Existing Test Kits
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size Value in USD)
-
5.1 Product Type
- 5.1.1 ELISA-based Tests
- 5.1.2 RT-PCR based Tests
- 5.1.3 Dengue IgG/IgM Rapid Test
- 5.1.4 Other Tests
-
5.2 End User
- 5.2.1 Hospitals
- 5.2.2 Diagnostic Centers
- 5.2.3 Other End Users
-
5.3 Geography
- 5.3.1 Asia-Pacific
- 5.3.1.1 India
- 5.3.1.2 Philippines
- 5.3.1.3 Indonesia
- 5.3.1.4 Malaysia
- 5.3.1.5 Vietnam
- 5.3.1.6 Thailand
- 5.3.1.7 Sri Lanka
- 5.3.1.8 Rest of Asia-Pacific
- 5.3.2 Americas
- 5.3.2.1 Brazil
- 5.3.2.2 Mexico
- 5.3.2.3 Nicaragua
- 5.3.2.4 Colombia
- 5.3.2.5 Honduras
- 5.3.2.6 Rest of Americas
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott
- 6.1.2 Abnova Corporation
- 6.1.3 PerkinElmer Inc. (Euroimmun AG)
- 6.1.4 Certest Biotec
- 6.1.5 DiaSorin S.p.A
- 6.1.6 F. Hoffmann-La Roche Ltd
- 6.1.7 InBios International Inc.
- 6.1.8 NovaTec Immundiagnostica GmbH
- 6.1.9 OriGene Technologies, Inc.
- 6.1.10 Thermo Fisher Scientific Inc.
- 6.1.11 Immundiagnostik AG
- 6.1.12 Quest Diagnostics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDengue Testing Industry Segmentation
As per the scope of the report, dengue is the most rapidly spreading mosquito-borne viral disease in the world. Blood testing detects viruses or antibodies produced in response to dengue infection. Therefore to control the spread of dengue fever, there are various diagnostic tests to reduce the number of deaths and focus on prevention and cure. The dengue testing market is segmented by product type, end-user, and by geography. By product type, the market is segmented into ELISA-based tests, RT-PCR-based tests, dengue IgG/IgM rapid tests, and other tests. By end-user, the market is segmented into hospitals, diagnostic centers, and other end-users. By geography, the market is segmented into Asia-Pacific and the Americas. The report offers the value (USD) for the above segments.
| Product Type | ELISA-based Tests | |
| RT-PCR based Tests | ||
| Dengue IgG/IgM Rapid Test | ||
| Other Tests | ||
| End User | Hospitals | |
| Diagnostic Centers | ||
| Other End Users | ||
| Geography | Asia-Pacific | India |
| Philippines | ||
| Indonesia | ||
| Malaysia | ||
| Vietnam | ||
| Thailand | ||
| Sri Lanka | ||
| Rest of Asia-Pacific | ||
| Geography | Americas | Brazil |
| Mexico | ||
| Nicaragua | ||
| Colombia | ||
| Honduras | ||
| Rest of Americas |
Dengue Testing Market Research FAQs
How big is the Dengue Testing Market?
The Dengue Testing Market size is expected to reach USD 436.19 million in 2024 and grow at a CAGR of 4.37% to reach USD 540.20 million by 2029.
What is the current Dengue Testing Market size?
In 2024, the Dengue Testing Market size is expected to reach USD 436.19 million.
Who are the key players in Dengue Testing Market?
Thermo Fisher Scientific Inc., InBios International, Inc., NovaTec Immundiagnostica GmbH, F. Hoffmann-La Roche Ltd. and Abbott are the major companies operating in the Dengue Testing Market.
Which is the fastest growing region in Dengue Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Dengue Testing Market?
In 2024, the North America accounts for the largest market share in Dengue Testing Market.
What years does this Dengue Testing Market cover, and what was the market size in 2023?
In 2023, the Dengue Testing Market size was estimated at USD 417.13 million. The report covers the Dengue Testing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Dengue Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Dengue Test Industry Report
Statistics for the 2024 Dengue Test market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Dengue Test analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
